Brief: Innovation Pharmaceuticals Receives Data Showing Brilacidin Inhibits Sars-Cov-2 (Covid-19) In A Human Cell Line
26/05/2020 14:03
May 26 (Reuters) - Innovation Pharmaceuticals Inc IPIX.PK :
* INNOVATION PHARMACEUTICALS RECEIVES DATA FROM PUBLIC
HEALTH
RESEARCH INSTITUTE SHOWING BRILACIDIN INHIBITS SARS-COV-2
(COVID-19) IN A HUMAN CELL LINE
* INNOVATION PHARMACEUTICALS INC - DATA SUPPORTS
BRILACIDIN'S
POTENTIAL TO PREVENT SARS-COV-2 BINDING TO HACE2 RECEPTOR
Source text for Eikon: ID:nGNX5Ht8rC
Further company coverage: IPIX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review